Miromatrix CEO Jeff Ross Shares the Bold Plan to Eliminate the Organ Transplant Waiting List

Medtech Talk Podcast | Episode 122

EPISODE 122

Miromatrix straddles the line between biotech and medtech. The start-up is developing a line of “ghost organs” that can be used in humans. The technology is moving fast, and Ross hopes to have clinical trials up and running by the end of 2020. The future is here. Also, I’ll announce a keynote speaker for the May 30 Medtech Conference.

Podcast Guest

Jeff Ross

Jeff Ross, PhD

CEO

Miromatrix

Dr. Ross brings more than 20 years of biomedical research, management and regulatory experience in regenerative medicine, biologics, and medical devices to Miromatrix including concept development, preclinical, clinical, manufacturing, and commercialization. He has held various technical and management positions at Guidant, Athersys and SurModics. Since coming to Miromatrix in 2010 he has been pivotal in the development, manufacturing and regulatory clearance of the innovative MIROMESH and MIRODERM product lines. He has spearheaded development, global patent strategy, and fundraising for the revolutionary whole organ transplant program and its key decellularization technology. Dr. Ross has over 30 patents along with scientific publications in Nature and other peer-reviewed journals. He holds a Master’s degree in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Minnesota.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the Medtech Talk Podcast, please complete the application today.

Meet Our Host

TOM SALEMI

Tom Salemi

A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!